Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566

Files
Nelson2024Correction-CCBY.pdf (154.18 KB)
Date
2024-10-25
Authors
Nelson, Ryan S.
Seligson, Nathan D.
Bottiglieri, Sal
Carballido, Estrella
Del Cueto, Alex
Imanirad, Iman
Levine, Richard
Parker, Alexander S.
Swain, Sandra M.
Tillman, Emma M.
Hicks, J. Kevin
Language
American English
Embargo Lift Date
Department
Pharmacology and Toxicology, School of Medicine
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
MDPI
Can't use the file because of accessibility barriers? Contact us with the title of the item, permanent link, and specifics of your accommodation need.
Abstract
Description
Keywords
UGT1A1, Pharmacogenetics, Irinotecan, Pazopanib, Nilotinib, Belinostat, Cancer, Genotype, Precision medicine, Gilbert’s syndrome
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Nelson RS, Seligson ND, Bottiglieri S, et al. Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566. Cancers (Basel). 2024;16(21):3595. Published 2024 Oct 25. doi:10.3390/cancers16213595
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Cancers
Rights
Attribution 4.0 International Creative Commons licenses
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
https://hdl.handle.net/1805/44790
DOI
https://doi.org/10.3390/cancers16213595
Version
Final published version
Full Text Available at
This item is under embargo {{howLong}}
Collections
Open Access Policy Articles